IP Considerations Following FDA Announcement on Flexibility for Cell and Gene Therapies
Key Takeaways: Manufacturing processes of cell and gene therapies (CGTs) may remain fluid well into development and even after FDA approval, and therefore sponsors of CGTs may benefit from patent...
Sheila Swaroop Comments on USPTO Memo on U.S. Manufacturing Factors in AIA Reviews
In the Law360 article “Manufacturing Factor Adds More New Twists to AIA Cases,” Knobbe Martens partner Sheila Swaroop weighed in on the U.S. Patent & Trademark Office’s latest memo regarding...
Knobbe Martens Shortlisted in Multiple Categories for 2026 Life Sciences Patent Network Awards
IRVINE, Calif., March 5, 2026 – Highlighting its strength in the life sciences industry, Knobbe Martens is pleased to share that the firm is shortlisted in multiple categories for the...